Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 143 No. 2728 (2013)

Current cholesterol guidelines and clinical reality: a comparison of two cohorts of coronary artery disease patients

  • Alexander Vonbank
  • Christoph Saely
  • Philipp Rein
  • Daniel Sturn
  • Heinz Drexel
DOI
https://doi.org/10.4414/smw.2013.13828
Cite this as:
Swiss Med Wkly. 2013;143:w13828
Published
30.06.2013

References

  1. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985;110:1100–07.
  2. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005;96:53E–9E.
  3. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):S1–113.
  4. Jeger R, Dieterle T. Statins: have we found the Holy Grail? Swiss Med Wkly. 2012;142:w13515.
  5. Braunersreuther V, Mach F, Montecucco F. Statins and stent thrombosis. Swiss Med Wkly. 2012;142:w13525.
  6. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
  7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.
  8. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.
  9. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.
  10. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.
  11. AAS Guidelines. 2013; http://www.aas.at.
  12. AGLA guidelines. 2013; http://www.agla.ch.
  13. Vonbank A, Saely CH, Rein P, Beer S, Breuss J, Boehnel C. Insulin resistance is associated with the metabolic syndrome and is not directly linked to coronary artery disease. Clin Chim Acta. 2011;412:1003–7.
  14. Saely CH, Rein P, Vonbank A, Huber K, Drexel H. Type 2 diabetes and the progression of visualized atherosclerosis to clinical cardiovascular events. Int J Cardiol. 2012.
  15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.
  16. Zimmet P, Alberti G, de Court. New classification and criteria for diabetes: moving the goalposts closer. Med J Aust. 1998;168:593–4.
  17. Drexel H, Amann FW, Rentsch K, Neuenschwander C, Luethy A, Khan SI. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol. 1992;70:436–40.
  18. Drexel H, Amann FW, Beran J, Rentsch K, Candinas R, Muntwyler J. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation. 1994;90:2230–5.
  19. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
  20. Qayyum R, Chattha AA, Bhullar N, Katsetos M, Schulman P. Achievement of national cholesterol education program goals by patients with dyslipidemia in rural ambulatory care settings. Prev Cardiol. 2006;9:192–7.
  21. Coon P, Zulkowski K. Adherence to American Diabetes Association standards of care by rural health care providers. Diabetes Care. 2002;25:2224–9.
  22. Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF. Achieving Optimal Lipid Goals in Patients With Coronary Artery Disease. Am J Cardiol. 2011.
  23. Roden M, Huber K. Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: the Austrian Hospital Screening Project (HSP). Wien Klin Wochenschr. 2008;120:558–65.
  24. Kitkungvan D, Lynn Fillipon NM, Dani SS, Downey BC. Low-density lipoprotein cholesterol target achievement in patients at high risk for coronary heart disease. J Clin Lipidol. 2010;4:293–7.
  25. Martin SS, Gosch K, Kulkarni KR, Spertus JA, Mathews R, Ho PM. Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. Am Heart J. 2013;165:26–33.

Most read articles by the same author(s)